OCTP.L

Oxford Cannabinoid Technologies Holdings Plc
Oxford Cannabinoid - OCT Company Update with Doceo
3rd April 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0207J
Oxford Cannabinoid Tech.Holdings
03 April 2024
 

Logo, company name Description automatically generated

 

OCT Company Update with Doceo

 

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), a clinical stage biopharmaceutical company focused on the development and commercialisation of innovative cannabinoid medicines, is pleased to share the following Company Update video with Doceo.

Clarissa Sowemimo-Coker, Chief Executive Officer, discusses the significant unmet need for non-addictive treatments to help people living with debilitating conditions in a global pain market that is estimated to be worth £75bn by 2027.

 


For further information on Doceo please visit www.doceo.tv or contact the team on info@doceo.tv

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAZZGGDDZFGDZM]]>
TwitterFacebookLinkedIn